Rates today
  • Prime rate 6.75% flat
  • Fed funds 3.63% flat
  • SOFR 3.66% up0.03
  • Treasury 1Y 4.00% down0.04
  • Treasury 10Y 4.72% flat
Updated: EST

This product uses the FRED® API but is not endorsed or certified by the Federal Reserve Bank of St. Louis.

Applications Open

Alzheimer’s Drug-Development Program (U01 Clinical Trial Optional)

Deadline
November 5, 2027
Funding
Up to $1,500,000
Geography
National
Funder
National Institutes of Health

Grant Overview

The goal of this Notice of Funding Opportunity (NOFO) is to provide funding support for the pre-clinical and early stage clinical (Phase I) development of novel small-molecule and biologic drug candidates that prevent Alzheimer’s disease (AD), slow its progression, or treat its cognitive and behavioral symptoms. Participants in this program will receive funding for therapy development activities such as medicinal chemistry; pharmacokinetics (PK); Absorption, Distribution, Metabolism, Excretion,…

Eligibility and Program Details